“People with Parkinson’s routinely tell us they wish for some symptomatic relief - perhaps a good night sleep - not a miracle cure in 10 years from now.”
Dr Wayne Markman, CEO
Mr Peter Carre: CO-FOUNDER & CHAIRMAN
AB (Harvard), JD (Boston)
Peter is an experienced lawyer, company advisor and director with a strong track record in commercialising innovative med/bio-technologies. Peter has developed many companies out of research institutes and universities, raised capital, and led senior technology management teams.
He received a lifetime achievement award for corporate governance from the AICD, was an APEC Summit (Shanghai) keynote speaker on Medtech investing in Asia Pacific, a former Garvan Institute of Medical Research Commercialisation Director and a co-founder of Xcelerator, Australia's first life sciences incubator which listed several Med/Bio-tech companies on the ASX.
Dr Wayne Markman: CO-FOUNDER & CEO
BEcon (Macalester), MBA (Harvard), BChiro and MChiro (Macquarie)
Wayne is an experienced healthcare startup CEO. He was previously a corporate finance and venture capital professional and is also a qualified Doctor of Chiropractic. He has successfully commercialised a number of different medical technologies, navigated the regulatory process in several international jurisdictions and built global medical supply and distribution channels.
Wayne was previously a Director at Credit Suisse where he structured M&A and capital market transactions in the tech and healthcare sectors. In his spare time he is a lecturer in Investment Management at University Technology Sydney (UTS) and plays tennis and football.
Dr Ann Liebert: CO-FOUNDER & SCIENTIFIC ADVISOR
BApp Science - Physio, PhD (USYD)
Ann is a world-renowned researcher in Medical Photobiomics, Coordinator of Photomolecular Research, San Hospital, a qualified Physiotherapist and Adjunct Senior Lecturer Department of Medicine at The University of Sydney. Research projects include metabolic disease/pre-diabetes insulin resistance trial-of-concept case studies and multi-centre Parkinson's translational trials - in Sydney, Brisbane and Adelaide.
Ann was a keynote speaker at the International Society for Optics and Photonics (SPIE Photonics West) in San Francisco in February 2020. Ann is currently leading the development of SYMBYX's therapies for neurodegenerative and obesity related disorders, commencing with a system for alleviating Parkinson’s related symptoms.
Dr Brian Bicknell: CO-FOUNDER & SCIENTIFIC ADVISOR
BScience (USYD), PhD (UNSW)
Brian was formerly an Honorary Fellow of Faculty Health Sciences at ACU and a Visiting Research Fellow at Australasian Research Institute, San Hospital. Brian pioneered the fundamental research investigating the effect of light on the microbiome, both originally in mice models and recently in human models. Brian has co-published many research papers on Photobiomodulation and Photobiomics with Dr. Liebert.
Brian presented the first report of results of our Parkinson’s trials at the International Society for Optics and Photonics (SPIE Photonics West) in San Francisco in February 2020. Brian is integrally involved in conducting the Parkinson's and Obesity trials for SYMBYX and in furthering the studies into the effect of light on the microbiome.
Prof Branko Celler: ENGINEERING & REGULATORY ADVISOR
PhD (John Hopkins, UNSW)
Branko is an internationally recognised biomedical researcher with vast experience in developing biomedical devices for chronic disease management at home. He is widely regarded as a pioneer in the Australian telehealth industry. In addition to his distinguished academic career, Branko has managed several biomedical products through the regulatory process and on to international distribution.
Branko is also a Fellow of several Societies including the Australian Academy of Technology and Engineering and the IEEE, the world’s largest professional body. He has raised over $18 million from industry and nationally competitive grants.
Tanya McNeill: BUSINESS DEVELOPMENT DIRECTOR
BEcon, Grad Dip Psychology (Macquarie)
Tanya is a strategic business development specialist with more than 20 years’ experience in tier-one global FMCG organisations. She has embraced opportunities to make a difference in people’s lives, promoting the benefits of SYMBYX’s breakthrough devices and therapies. Her focus is successful outcomes, for both people and corporations, that make a real difference.
What sets Tanya apart is her energy, warmth, curiosity, and a desire to connect and grow relationships, whether that’s with patients, clinicians, practice managers or scientists. Tanya’s has an ability to place people first, making them willing collaborators in developing initiatives that make a difference.
Ann Schomakers: CUSTOMER RELATIONS MANAGER
BA Business Administration (Hochschule Wismar University)
Ann was born and raised in Hamburg, Germany and studied Business Administration majoring in Finance and Control. She consolidated her academic studies consulting to numerous European listed stock exchange companies before taking up management roles with several branded goods ventures.
Ann brings with her significant international experience in business administration and financial management as well as years of experience in customer relations. She’s an energetic and motivated member of the team with enthusiasm for non-invasive laser therapy and helping SYMBYX customers all over the world.
Research
There are currently 4,000 + peer-reviewed scientific studies reporting on the incident-free, protective and restorative properties of light therapy for a number of health conditions.
Home Use
SYMBYX’s medical-grade PDCare laser is flexible, compact and easy to use at home device. A non-surgical and non-thermal treatment.
Benefits
Positive changes include motor improvements, better sleep, lightened mood, reduced muscle pain and even returned sense of smell.
Use left/right arrows to navigate the slideshow or swipe left/right if using a mobile device
Choosing a selection results in a full page refresh.
Press the space key then arrow keys to make a selection.
